Licogliflozin

DB15048InvestigationalSmall molecule

Licogliflozin is under investigation in clinical trial NCT03320941 (A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With Obesity).

Mechanism: Pharmacologically active on Sodium/glucose cotransporter 2 and Sodium/glucose cotransporter 1
Curator reviewed
Formula / weight: C₂₃H₂₈O₇ · 416.47 g/mol (avg)
Code names: LIK066

Resolves to

Compound

UNII57J06X6EI0CAS1291094-73-9

Structure

InChIKeyXFJAMQQAAMJFGB-ZQGJOIPISA-NSMILESCCC1=CC=C(C=C1CC1=CC2=C(OCCO2)C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O

Targets

P31639SLC5A2P13866SLC5A1

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

12Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Licogliflozin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account